Evidence map›Paper›PMID 38195707›Full record

ArticleNature cell biology2024

EPAC1 enhances brown fat growth and beige adipogenesis.

Laia Reverte-Salisa, Sana Siddig, Staffan Hildebrand, Xi Yao, Jelena Zurkovic, Michelle Y Jaeckstein, Joerg Heeren, Frank Lezoualc'h, Natalie Krahmer, Alexander Pfeifer

Open access · hybridAbstract read
In one paragraph

Article in Nature cell biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
12.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 39 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Mechanical interplay between adipose tissues and disease progression.Bioengineering & translational medicine · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Laia Reverte-SalisaInstitute of Pharmacology and Toxicology, University Hospital, University of Bonn, Bonn, Germany.ORCID 0000-0002-9216-682X
Sana Siddig *Institute of Pharmacology and Toxicology, University Hospital, University of Bonn, Bonn, Germany.ORCID 0000-0001-9982-2191
Staffan Hildebrand *Institute of Pharmacology and Toxicology, University Hospital, University of Bonn, Bonn, Germany.ORCID 0000-0003-1889-907X
Xi YaoInstitute of Pharmacology and Toxicology, University Hospital, University of Bonn, Bonn, Germany.
Jelena ZurkovicInstitute of Pharmacology and Toxicology, University Hospital, University of Bonn, Bonn, Germany.
Michelle Y JaecksteinInstitute of Biochemistry and Molecular Cell Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Joerg HeerenInstitute of Biochemistry and Molecular Cell Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0002-5647-1034
Frank Lezoualc'hInstitute of Cardiovascular and Metabolic Diseases, Inserm UMR-1297, Université Toulouse -Paul Sabatier, Toulouse, France.
Natalie KrahmerInstitute for Diabetes and Obesity, Helmholtz Center Munich, Neuherberg, Germany.ORCID 0000-0003-4063-7367
Alexander PfeiferInstitute of Pharmacology and Toxicology, University Hospital, University of Bonn, Bonn, Germany. alexander.pfeifer@uni-bonn.de.ORCID 0000-0001-8805-6831
University of Bonn · DEUniversität Hamburg · DEHelmholtz Zentrum München · DEUniversité Toulouse III - Paul Sabatier · FR

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) 214362475/GRK1873Deutsche Forschungsgemeinschaft (German Research Foundation) 335447717-SFB1328Deutsche Forschungsgemeinschaft (German Research Foundation) 397484323-TRR 259Deutsche Forschungsgemeinschaft (German Research Foundation) 450149205-TRR333
6 · The paper itself

Abstract

Brown adipose tissue (BAT) is a central thermogenic organ that enhances energy expenditure and cardiometabolic health. However, regulators that specifically increase the number of thermogenic adipocytes are still an unmet need. Here, we show that the cAMP-binding protein EPAC1 is a central regulator of adaptive BAT growth. In vivo, selective pharmacological activation of EPAC1 increases BAT mass and browning of white fat, leading to higher energy expenditure and reduced diet-induced obesity. Mechanistically, EPAC1 coordinates a network of regulators for proliferation specifically in thermogenic adipocytes, but not in white adipocytes. We pinpoint the effects of EPAC1 to PDGFRα-positive preadipocytes, and the loss of EPAC1 in these cells impedes BAT growth and worsens diet-induced obesity. Importantly, EPAC1 activation enhances the proliferation and differentiation of human brown adipocytes and human brown fat organoids. Notably, a coding variant of RAPGEF3 (encoding EPAC1) that is positively correlated with body mass index abolishes noradrenaline-induced proliferation of brown adipocytes. Thus, EPAC1 might be an attractive target to enhance thermogenic adipocyte number and energy expenditure to combat metabolic diseases.

Indexed as

AdipogenesisAdipose Tissue, BrownAdipocytes, BrownAdipose Tissue, WhiteCell DifferentiationEnergy MetabolismGuanine Nucleotide Exchange FactorsHumansObesityGuanine Nucleotide Exchange FactorsRAPGEF3 protein, human

Identifiers

PMID38195707
PMCPMC10791580
OpenAlexW4390706594

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.